Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, we democratize access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. We provide affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. Our lead offering, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains.
Founded in 2017 and privately funded by visionary investors, we are headquartered in Boston, MA with European labs in Cambridge, UK. As a reflection of our relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.
Total Funding: $75 M
Funding Stage: Series C
Business Stage: Scaling Up
Market: B2B
Company Size: 101 to 250
Founded: 2017
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Alloy Therapeutics
Technology Specialist, Nanoparticles
Lexington, Massachusetts
Technology Specialist, mRNA & ASO
Lexington, Massachusetts
Senior Scientist, Phage Display
Lexington, Massachusetts
Scientist, T Cell Biology
Lexington, Massachusetts
Scientist, Genetically Engineered Organisms
Lexington, Massachusetts
